NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Free Report) – HC Wainwright raised their FY2026 earnings per share (EPS) estimates for shares of NewAmsterdam Pharma in a research note issued to investors on Friday, November 6th. HC Wainwright analyst L. Egana-Gorrono now forecasts that the company will post earnings per share of ($1.50) for the year, up from their previous estimate of ($1.82). HC Wainwright currently has a “Buy” rating and a $52.00 target price on the stock. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.62) per share. HC Wainwright also issued estimates for NewAmsterdam Pharma’s Q4 2026 earnings at ($0.43) EPS, FY2027 earnings at ($1.48) EPS, FY2028 earnings at $1.30 EPS, FY2029 earnings at $5.72 EPS and FY2030 earnings at $7.70 EPS.
NAMS has been the subject of a number of other research reports. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Sunday, November 1st. Jefferies Financial Group reiterated a “buy” rating and set a $45.00 target price on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Thursday, October 15th. Royal Bank Of Canada lowered their target price on shares of NewAmsterdam Pharma from $50.00 to $42.00 and set an “outperform” rating on the stock in a research note on Monday, October 5th. Finally, Needham & Company LLC dropped their price target on shares of NewAmsterdam Pharma from $48.00 to $46.00 and set a “buy” rating for the company in a research report on Thursday, November 5th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $48.70.
Read Our Latest Stock Report on NewAmsterdam Pharma
NewAmsterdam Pharma Price Performance
Shares of NewAmsterdam Pharma stock opened at $19.00 on Tuesday. The firm has a market capitalization of $2.27 billion, a PE ratio of -11.24 and a beta of 0.15. The company’s fifty day moving average price is $21.96 and its two-hundred day moving average price is $29.45. NewAmsterdam Pharma has a 52-week low of $17.90 and a 52-week high of $42.21.
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.33. NewAmsterdam Pharma had a negative return on equity of 31.04% and a negative net margin of 789.95%. The firm had revenue of $19.16 million during the quarter, compared to analysts’ expectations of $8.82 million.
Insider Buying and Selling at NewAmsterdam Pharma
In other NewAmsterdam Pharma news, insider Johannes Kastelein sold 50,246 shares of the stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $25.03, for a total transaction of $1,257,657.38. Following the completion of the transaction, the insider directly owned 69,302 shares in the company, valued at $1,734,629.06. This represents a 42.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director John W. Smither sold 1,600 shares of NewAmsterdam Pharma stock in a transaction on Friday, September 4th. The shares were sold at an average price of $25.32, for a total value of $40,512.00. Following the transaction, the director directly owned 8,760 shares of the company’s stock, valued at approximately $221,803.20. The trade was a 15.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 176,846 shares of company stock worth $4,661,919 over the last three months. Company insiders own 12.74% of the company’s stock.
Institutional Investors Weigh In On NewAmsterdam Pharma
Several large investors have recently made changes to their positions in NAMS. Parallel Advisors LLC grew its position in shares of NewAmsterdam Pharma by 43.7% during the 3rd quarter. Parallel Advisors LLC now owns 2,012 shares of the company’s stock worth $49,000 after buying an additional 612 shares during the period. AlphaCentric Advisors LLC increased its stake in shares of NewAmsterdam Pharma by 4.6% in the 3rd quarter. AlphaCentric Advisors LLC now owns 15,549 shares of the company’s stock valued at $378,000 after acquiring an additional 681 shares during the last quarter. KBC Group NV bought a new stake in shares of NewAmsterdam Pharma in the 1st quarter valued at about $37,000. Kornitzer Capital Management Inc. KS increased its stake in shares of NewAmsterdam Pharma by 1.3% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 141,711 shares of the company’s stock valued at $3,446,000 after acquiring an additional 1,778 shares during the last quarter. Finally, Arizona State Retirement System raised its position in shares of NewAmsterdam Pharma by 34.6% in the 2nd quarter. Arizona State Retirement System now owns 16,656 shares of the company’s stock valued at $564,000 after acquiring an additional 4,281 shares during the period. Institutional investors own 89.89% of the company’s stock.
NewAmsterdam Pharma Company Profile
NewAmsterdam Pharma is a biopharmaceutical company focused on developing oral treatments for cardiometabolic diseases, particularly conditions involving elevated cholesterol and cardiovascular risk. The company’s lead investigational medicine is obicetrapib, an oral inhibitor of cholesteryl ester transfer protein (CETP) being studied to lower LDL cholesterol.
NewAmsterdam has evaluated obicetrapib both on its own and in combination with ezetimibe, including in clinical studies involving people with inherited high cholesterol or established cardiovascular disease whose cholesterol remains elevated despite existing treatment.
Read More
- Five stocks we like better than NewAmsterdam Pharma
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
